LY-341495 is a research drug developed by the pharmaceutical company
Eli Lilly
Eli Lilly (July 8, 1838 – June 6, 1898) was an American soldier, pharmacist, chemist, and businessman who founded the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War and ...
, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (
mGluR2/3).
It is used in scientific research in several different areas, showing
antidepressant effects in animal models, increasing the behavioural effects of hallucinogenic drugs in animal tests, and increasing the
analgesic effects of
μ-opioid agonists, as well as modulating
dopamine receptor
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through diffe ...
function.
The 1-fluorocyclopropane analog has a superior
pharmacokinetic profile and similar mGluR
2/3 affinity, and making a
prodrug from this with the heptyl ester increases bioavailability still further.
See also
*
CECXG
CECXG (3'-ethyl-LY-341,495) is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors ( mGluR2/3), with reasonable selectivity for mGluR3. While it is some five times less potent than LY ...
References
{{Metabotropic glutamate receptor modulators
Eli Lilly and Company brands
MGlu2 receptor antagonists
MGlu3 receptor antagonists
Xanthenes